A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion

A novel genetic approach for the control of virus replication was used for the design of a conditionally replicating human immunodeficiency virus (HIV) variant, HIV-rtTA. HIV-rtTA gene expression and virus replication are strictly dependent on the presence of a non-toxic effector molecule, doxycycli...

Full description

Saved in:
Bibliographic Details
Published inJournal of general virology Vol. 93; no. Pt 9; pp. 2017 - 2027
Main Authors LEGRAND, Nicolas, VAN DER VELDEN, Gisela J, HO TSONG FANG, Raphaël, DOUAISI, Marc, WEIJER, Kees, DAS, Atze T, BLOM, Bianca, UITTENBOGAART, Christel H, BERKHOUT, Ben, CENTLIVRE, Mireille
Format Journal Article
LanguageEnglish
Published Reading Society for General Microbiology 01.09.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A novel genetic approach for the control of virus replication was used for the design of a conditionally replicating human immunodeficiency virus (HIV) variant, HIV-rtTA. HIV-rtTA gene expression and virus replication are strictly dependent on the presence of a non-toxic effector molecule, doxycycline (dox), and thus can be turned on and off at will in a graded and reversible manner. The in vivo replication capacity, pathogenicity and genetic stability of this HIV-rtTA variant were evaluated in a humanized mouse model of haematopoiesis that harbours lymphoid and myeloid components of the human immune system (HIS). Infection of dox-fed BALB Rag/γc HIS (BRG-HIS) mice with HIV-rtTA led to the establishment of a productive infection without CD4(+) T-cell depletion. The virus did not show any sign of escape from dox control for up to 10 weeks after the onset of infection. No reversion towards a functional Tat-transactivating responsive (TAR) RNA element axis was observed, confirming the genetic stability of the HIV-rtTA variant in vivo. These results demonstrate the proof of concept that HIV-rtTA replicates efficiently in vivo. HIV-rtTA is a promising tool for fundamental research to study virus-host interactions in vivo in a controlled fashion.
Bibliography:Part of the Human Vaccine Consortium, ‘Grand Challenge in Global Health #4: devise reliable testing systems for new vaccines’.
Present address: Rensselaer Polytechnic Institute, Troy, NY, USA.
Present address: InnaVirVax SA, Evry, France.
Present address: Axenis S. A. S., Paris, France.
ISSN:0022-1317
1465-2099
DOI:10.1099/vir.0.042796-0